Today's Research Reports on ESSA Pharma, OrganiGram, IntelliPharmaCeutics International and Centric Health
NEW YORK, NY / ACCESSWIRE / January 22, 2019 /The Market Wealth Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://marketwealthreport.com and get exclusive access to our numerous research reports and market updates.
The Market Wealth Report Initiates Coverage on:
ESSA Pharma Inc.
https://marketwealthreport.com/report/EPI.V/
OrganiGram Holdings Inc.
https://marketwealthreport.com/report/OGI.V/
IntelliPharmaCeutics International Inc.
https://marketwealthreport.com/report/IPCI.TO/
Centric Health Corporation
https://marketwealthreport.com/report/CHH.TO/
ESSA Pharma's stock had no change Monday, to close the day at $5.40. The stock recorded a trading volume of 1,625 shares, which was above its three months average volume of 1,375 shares. In the last year, ESSA Pharma's shares have traded in a range of 2.50 - 7.15. The share price has gained 116% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.61 is lower than its 200-day moving average of $4.12. Shares of ESSA Pharma have gained approximately 86.21 percent year-to-date.
Access The Market Wealth's ESSA Pharma Inc. Research Report:
https://marketwealthreport.com/report/EPI.V/
On Monday, shares of OrganiGram Holdings recorded a trading volume of 429,458 shares, which was below the three months average volume of 1,132,122 shares. The stock ended the day 1.26% lower at $6.26. The share price has fallen 26.78% from its 52week high with a52 week trading range of 3.26 - 8.55. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $5.22 is lower than its 200-day moving average of $5.75. Shares of the company are trading at a Price to Earnings ratio of 38.88. Shares of OrganiGram Holdings have gained approximately 34.62 percent year-to-date.
Access The Market Wealth's OrganiGram Holdings Inc. Research Report:
https://marketwealthreport.com/report/OGI.V/
IntelliPharmaCeutics International's stock had no change Monday, to close the day at $0.41. The stock recorded a trading volume of 1,500 shares, which was below its three months average volume of 20,532 shares. In the last year, IntelliPharmaCeutics International's shares have traded in a range of 0.27 - 12.30. The share price has gained 51.85% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.35 is lower than its 200-day moving average of $2.32. Shares of IntelliPharmaCeutics International have gained approximately 28.13 percent year-to-date.
Access The Market Wealth's IntelliPharmaCeutics International Inc. Research Report:
https://marketwealthreport.com/report/IPCI.TO/
On Monday, shares of Centric Health recorded a trading volume of 404,290 shares, which was above the three months average volume of 246,764 shares. The stock ended the day 5.71% higher at $0.37. The share price has fallen 38.33% from its 52week high with a52 week trading range of 0.20 - 0.60. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.29 is equal to its 200-day moving average of $0.29. Shares of Centric Health have gained approximately 27.59 percent year-to-date.
Access The Market Wealth's Centric Health Corporation Research Report:
https://marketwealthreport.com/report/CHH.TO/
Our Actionable Research on ESSA Pharma Inc. (TSXV:EPI.V), OrganiGram Holdings Inc. (TSXV:OGI.V), IntelliPharmaCeutics International Inc. (TSX:IPCI.TO) and Centric Health Corporation (TSX:CHH.TO) can be downloaded free of charge at The Market Wealth Report.
The Market Wealth Report
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
The Market Wealth Report has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketWealthReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketWealthReport.com is neither a registeredbroker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketwealthreport.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
The Market Wealth Report, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
contact@marketwealthreport.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Market Wealth Report
